Brain, Vol. 112, No. 3, 727-747, 1989
© 1989 Guarantors of Brain
research-article |
INCLUSION BODY MYOSITIS
OBSERVATIONS IN 40 PATIENTS
Department of Neurology Mayo Clinic, Rochester, MN, USA
Correspondence to:
Correspondence to: Dr. A. G. Engel, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
SUMMARY
Inclusion body myositis (IBM) was suspected on light microscopic grounds in 48 of 170 consecutive patients with inflammatory myopathies. One or more vacuoles containing membranous material, groups of atrophic fibres, and an autoaggressive endomysial inflammatory exudate occurred in 100, 96 and 92% of the muscle specimens All three of these features were present in 88% of the specimens Electron microscopy confirmed the presence of filamentous inclusions in 40 of 43 patients The inclusions are typically near vacuoles and a minimum of three vacuolated fibres must be scrutinized to detect them with confidence. There is no electromyographic pattern that can reliably distinguish IBM from other inflammatory myopathies The typical clinical features in the patients diagnosed by histological criteria as IBM were: insidious onset after age 50 yrs with painless, proximal lower extremity weakness, slow but relentless progression with selectively severe involvement of quadriceps, iliopsoas, tibialis anterior, biceps and triceps muscles; relatively early depression of the knee reflexes; and a normal or mildly elevated serum creatine kinase level The male : female ratio was 3 : 1. Distal weakness occurred in about 50%, but only in 35% was it as great or greater than proximal weakness. Significant associated illnesses include other autoimmune disorders (15%), diabetes melhtus (20%), and diffuse peripheral neuropathy (18%). Prednisone treatment at dose levels frequently effective in polymyositis failed to prevent disease progression in those patients observed for 2 or more years. Our findings support the notion that IBM is a distinct entity in which a set of pathological features is associated with a constellation of clinical findings.
Received June 7, 1988. Revised August 12, 1988. Accepted August 17, 1988.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A A Amato and R J Barohn Inclusion body myositis: old and new concepts J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A A Amato and R J Barohn Evaluation and treatment of inflammatory myopathies J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1060 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Needham, I James, A Corbett, T Day, F Christiansen, B Phillips, and F L Mastaglia Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1056 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vattemi, P. Tonin, M. Marini, M. L. Guadagnin, B. Dal Pra, A. Simonati, M. Filosto, and G. Tomelleri Sarcoidosis and inclusion body myositis Rheumatology, September 1, 2008; 47(9): 1433 - 1435. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chahin and A. G. Engel Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM Neurology, February 5, 2008; 70(6): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Oh, K. A. Brumfield, T. L. Hoskin, K. A. Stolp, J. A. Murray, and J. R. Basford Dysphagia in Inflammatory Myopathy: Clinical Characteristics, Treatment Strategies, and Outcome in 62 Patients Mayo Clin. Proc., April 1, 2007; 82(4): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kitazawa, K. N. Green, A. Caccamo, and F. M. LaFerla Genetically Augmenting A{beta}42 Levels in Skeletal Muscle Exacerbates Inclusion Body Myositis-Like Pathology and Motor Deficits in Transgenic Mice Am. J. Pathol., June 1, 2006; 168(6): 1986 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Amoura, P. Duhaut, D. L. T. Huong, B. Wechsler, N. Costedoat-Chalumeau, C. Frances, P. Cacoub, T. Papo, S. Cormont, Y. Touitou, et al. Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1279 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. A. Badrising, G. M.Th. Schreuder, M. J. Giphart, K. Geleijns, J. J.G.M. Verschuuren, A. R. Wintzen, and the Dutch IBM Study Group Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis Neurology, December 28, 2004; 63(12): 2396 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Voermans, M. Vaneker, G. J.D. Hengstman, H. J. ter Laak, C. Zimmerman, H. J Schelhaas, and M. J. Zwarts Primary respiratory failure in inclusion body myositis Neurology, December 14, 2004; 63(11): 2191 - 2192. [Full Text] [PDF]
|
|
|
|
|
|
G. Massawi, P. Hickling, D. Hilton, and C. Patterson Inclusion body myositis evolving in systemic lupus erythrematosus? A case report Rheumatology, August 1, 2003; 42(8): 1012 - 1014. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Greenberg, D. Sanoudou, J. N. Haslett, I. S. Kohane, L. M. Kunkel, A. H. Beggs, and A. A. Amato Molecular profiles of inflammatory myopathies Neurology, October 22, 2002; 59(8): 1170 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. De Bleecker, B. De Paepe, I. E. Vanwalleghem, and J. M. Schroder Differential expression of chemokines in inflammatory myopathies Neurology, June 25, 2002; 58(12): 1779 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis Neurology, November 13, 2001; 57(9): 1566 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rose, M. P. McDermott, C. A. Thornton, C. Palenski, W. B. Martens, and R. C. Griggs A prospective natural history study of inclusion body myositis: Implications for clinical trials Neurology, August 14, 2001; 57(3): 548 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dabby, D. J. Lange, W. Trojaborg, A. P. Hays, R. E. Lovelace, T. H. Brannagan, and L. P. Rowland Inclusion Body Myositis Mimicking Motor Neuron Disease Arch Neurol, August 1, 2001; 58(8): 1253 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buchbinder, A. Forbes, S. Hall, X. Dennett, and G. Giles Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study Ann Intern Med, June 19, 2001; 134(12): 1087 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. A. Badrising, M. Maat-Schieman, S. G. van Duinen, F. Breedveld, P. van Doorn, B. van Engelen, F. van den Hoogen, J. Hoogendijk, C. Howeler, A. de Jager, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study Neurology, November 14, 2000; 55(9): 1385 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H Brannagan, A. P Hays, D. J Lange, and W. Trojaborg The role of quantitative electromyography in inclusion body myositis J. Neurol. Neurosurg. Psychiatry, December 1, 1997; 63(6): 776 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Averbuch-Heller, I. Steiner, and O. Abramsky Neurologic Manifestations of Progressive Systemic Sclerosis Arch Neurol, December 1, 1992; 49(12): 1292 - 1295. [Abstract] [PDF]
|
|
|
|
 |
|
 D. H. Darrow, H. T. Hoffman, G. J. Barnes, and C. A. Wiley Management of Dysphagia in Inclusion Body Myositis Arch Otolaryngol Head Neck Surg, March 1, 1992; 118(3): 313 - 317. [Abstract] [PDF]
|
|
|
|
|
|
J. R. Mendell, Z. Sahenk, T. Gales, and L. Paul Amyloid Filaments in Inclusion Body Myositis: Novel Findings Provide Insight Into Nature of Filaments Arch Neurol, December 1, 1991; 48(12): 1229 - 1234. [Abstract] [PDF]
|
|
|
|
|
|
R. Massa, B. Weller, G. Karpati, E. Shoubridge, and S. Carpenter Familial Inclusion Body Myositis Among Kurdish-Iranian Jews Arch Neurol, May 1, 1991; 48(5): 519 - 522. [Abstract] [PDF]
|
|